Table of Contents
Highlights from the Literature
Cancer Immunology at the Crossroads
- Cancer Immunology at the Crossroads | AuthorChoiceDevikala Gurusamy, David Clever, Robert Eil and Nicholas P. RestifoCancer Immunol Res June 1 2017 5 (6) 426-433; DOI:10.1158/2326-6066.CIR-17-0117
Meeting Report
- Meeting ReportMatthew M. GubinCancer Immunol Res June 1 2017 5 (6) 434-438; DOI:10.1158/2326-6066.CIR-17-0224
Cancer Immunology Miniatures
- Cancer Immunology MiniaturesMichiko Harao, Marie-Andrée Forget, Jason Roszik, Hui Gao, Gildy V. Babiera, Savitri Krishnamurthy, Jessica A. Chacon, Shumin Li, Elizabeth A. Mittendorf, Sarah M. DeSnyder, Korrene F. Rockwood, Chantale Bernatchez, Naoto T. Ueno, Laszlo G. Radvanyi, Luis Vence, Cara Haymaker and James M. ReubenCancer Immunol Res June 1 2017 5 (6) 439-445; DOI:10.1158/2326-6066.CIR-16-0364
Triple-negative breast cancers have low somatic mutational loads. By culturing tumor-infiltrating lymphocytes with agonistic 4-1BB mAb, tumor-specific T cells were expanded and the mutations to which they responded identified, providing a rationale for adoptive T cell therapy.
Research Articles
- Research ArticlesXinqi Wu, Jingjing Li, Erin M. Connolly, Xiaoyun Liao, Jing Ouyang, Anita Giobbie-Hurder, Donald Lawrence, David McDermott, George Murphy, Jun Zhou, Matthias Piesche, Glenn Dranoff, Scott Rodig, Margaret Shipp and F. Stephen HodiCancer Immunol Res June 1 2017 5 (6) 446-454; DOI:10.1158/2326-6066.CIR-16-0385
Galectin-1 is often produced by tumors and is protumoral, proangiogenic, and immunosuppressive. Ipilimumab plus bevacizumab induced production of neutralizing antibodies to galectin-1, which correlated with better clinical outcomes in metastatic melanoma patients, highlighting its utility as a therapeutic target.
- Research ArticlesChristina Engel, Grethe Brügmann, Silke Lambing, Larissa H. Mühlenbeck, Samira Marx, Christian Hagen, Dorottya Horváth, Marion Goldeck, Janos Ludwig, Anna-Maria Herzner, Jan W. Drijfhout, Daniela Wenzel, Christoph Coch, Thomas Tüting, Martin Schlee, Veit Hornung, Gunther Hartmann and Jasper G. Van den BoornCancer Immunol Res June 1 2017 5 (6) 455-467; DOI:10.1158/2326-6066.CIR-16-0129-T
Solid tumors are generally hypoxic. RIG-I, but not IFNα, still functioned under hypoxia. Activating RIG-I and using vitamin C to scavenge free radicals in a melanoma model augmented NK and CD8+ T cell antitumor functions and prolonged survival.
- Research ArticlesJeremy B. Foote, Marleen Kok, James M. Leatherman, Todd D. Armstrong, Bridget C. Marcinkowski, Laureen S. Ojalvo, David B. Kanne, Elizabeth M. Jaffee, Thomas W. Dubensky Jr and Leisha A. EmensCancer Immunol Res June 1 2017 5 (6) 468-479; DOI:10.1158/2326-6066.CIR-16-0284
The efficacy and immune dynamics of STING modulation in the toleragenic tumor microenvironment were examined. Combining a STING agonist, PD-L1 blockade, and OX40R stimulation created an inflamed tumor microenvironment that recruited T cells and activated tumor-specific immunity.
- Research Articles | AuthorChoiceJun Zhou, Kathleen M. Mahoney, Anita Giobbie-Hurder, Fengmin Zhao, Sandra Lee, Xiaoyun Liao, Scott Rodig, Jingjing Li, Xinqi Wu, Lisa H. Butterfield, Matthias Piesche, Michael P. Manos, Lauren M. Eastman, Glenn Dranoff, Gordon J. Freeman and F. Stephen HodiCancer Immunol Res June 1 2017 5 (6) 480-492; DOI:10.1158/2326-6066.CIR-16-0329
Melanoma cells could secrete several splice variants of PD-L1. Secretion differed among patients, and was affected by checkpoint therapy, with some changes associated with progressive disease, and others with favorable outcomes, suggesting circulating PD-L1 as a dynamic biomarker.
- Research ArticlesLazar Vujanovic, Elizabeth C. Stahl, Angela D. Pardee, David A. Geller, Allan Tsung, Simon C. Watkins, Gregory A. Gibson, Walter J. Storkus and Lisa H. ButterfieldCancer Immunol Res June 1 2017 5 (6) 493-502; DOI:10.1158/2326-6066.CIR-16-0216
Low NK cell numbers, function, and infiltration into tumors predict poor outcomes for patients with hepatocellular carcinoma (HCC). Tumor-derived α-fetoprotein (AFP) from HCCs directly impacted NK cell function and viability, through both the AFP protein and AFP's low-molecular-mass cargo.
- Research ArticlesYu Mei, Lixiang Zhao, Yonghao Liu, Huanle Gong, Yuan Song, Lei Lei, Ying Zhu, Ziqi Jin, Shoubao Ma, Bo Hu, Qing Sun and Haiyan LiuCancer Immunol Res June 1 2017 5 (6) 503-514; DOI:10.1158/2326-6066.CIR-16-0240-T
Effective tumor vaccines activate both CD4+ and CD8+ T cells. A melanoma DNA vaccine delivered by a bacterial system that ensured presentation of both class I and class II peptides activated both arms of the adaptive immune response.
Volume 5, Issue 6